Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3

3 hours ago 2

Soumya Eswaran

Mon, November 17, 2025 astatine 8:05 AM CST 2 min read

Aristotle Atlantic Partners, LLC, an concern advisor, released its “Core Equity Strategy” third-quarter 2025 capitalist letter. The missive highlighted the marketplace review, quarterly performance, and attribution analysis. A transcript of the missive tin beryllium downloaded here. In the quarter, the US equity marketplace rallied, with the S&P 500 Index reaching 8.12%. Bonds besides finished higher successful the period, with the Bloomberg U.S. Aggregate Bond Index expanding 2.03%. The composite has returned 7.22% gross of fees (7.10% nett of fees) successful the quarter, underperforming the S&P 500 Index’s 8.12% gain. Security enactment led to the comparative underperformance of the strategy successful the quarter. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, Aristotle Atlantic Core Equity Strategy highlighted stocks specified arsenic Adaptive Biotechnologies Corporation (NASDAQ:ADPT). Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is simply a commercial-stage biotechnology company. The one-month instrumentality of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) was -20.92%, and its shares gained 201.28% of their worth implicit the past 52 weeks. On November 14, 2025, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) banal closed astatine $14.10 per share, with a marketplace capitalization of $2.159 billion.

Aristotle Atlantic Core Equity Strategy stated the pursuing regarding Adaptive Biotechnologies Corporation (NASDAQ:ADPT) successful its 3rd 4th 2025 capitalist letter:

"Adaptive Biotechnologies Corporation (NASDAQ:ADPT) contributed to show successful the 3rd 4th arsenic momentum continued successful its minimal residual illness (MRD) investigating business, anchored by its flagship clonoSEQ trial for MRD successful respective hematological cancers. During the quarter, the institution reported better-than-expected net and raised full-year guidance. Average selling terms (ASP) increases are complementing accelerating measurement growth."

Among Stocks Insiders Are Selling In March

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 26 hedge money portfolios held Adaptive Biotechnologies Corporation (NASDAQ:ADPT) astatine the extremity of the 2nd quarter, compared to 27 successful the erstwhile quarter. While we admit the imaginable of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.